Compare AbbVie Inc (ABBV) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs PPG Industries, Inc. — how do they compare? AbbVie Inc trades at $249.99 (market cap $438.19B), while PPG Industries, Inc. trades at $115.82 (market cap $25.67B). The key difference: AbbVie Inc is far larger — about 17.1× PPG Industries, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | PPG | |
|---|---|---|
Market Cap | $438.19B | $25.67B |
Sector | Health | Basic Materials |
52-Week High | $263.58 | $131.56 |
52-Week Low | $197.38 | $94.34 |
Enterprise Value | $502.45B | $31.54B |
Dividend Yield | 2.79% | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
PPG Industries trades at $119.72, up 2.19% on the day, with a bullish technical outlook supported by moving averages. The company reported Q2 2026 sales growth of 7% year-over-year but missed EPS estimates. Recent dividend hikes and strong cash flow highlight financial health, while valuation ratios like a P/E of 17.18 suggest reasonable pricing. Analyst consensus is positive with a $129.17 price target.
Outlook remains favorable due to consistent dividend growth and operational strength, though risks include cost pressures and mixed earnings performance. The stock offers a balanced opportunity with upside potential from analyst targets, but investors should monitor margin trends and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
